Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Palazestrant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025
    Olema to Present Ph3 OPERA-02 Trial of Palazestrant at SABCS 2025

    30 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/30/3177971/0/en/Olema-Oncology-to-Present-Trial-in-Progress-Poster-for-Phase-3-OPERA-02-Trial-of-Palazestrant-Plus-Ribociclib-at-SABCS-2025.html

    GLOBENEWSWIRE
    30 Oct 2025
    Share Share
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data
    Olema Oncology Unveils Phase 1B/2 Palazestrant + Ribociclib Data

    18 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/18/3168941/0/en/Olema-Oncology-Announces-New-Data-from-the-Phase-1b-2-Trial-of-Palazestrant-Plus-Ribociclib-in-ER-HER2-Metastatic-Breast-Cancer-at-ESMO-2025.html

    GLOBENEWSWIRE
    18 Oct 2025
    Share Share
    Olema Oncology, Pfizer Partner to Combine Palazestrant
    Olema Oncology, Pfizer Partner to Combine Palazestrant

    02 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/02/3142485/0/en/Olema-Oncology-Announces-New-Clinical-Trial-Agreement-with-Pfizer-to-Combine-Palazestrant-with-Atirmociclib-in-ER-HER2-Metastatic-Breast-Cancer.html

    GLOBENEWSWIRE
    02 Sep 2025
    Share Share
    Olema Oncology Reports Q2 2024 Results And Corporate Update
    Olema Oncology Reports Q2 2024 Results And Corporate Update

    06 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/06/2925417/0/en/Olema-Oncology-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    06 Aug 2024
    Share Share
    Olema Presents Promising Palazestrant + Ribociclib Data At ESMO Breast Congress
    Olema Presents Promising Palazestrant + Ribociclib Data At ESMO Breast Congress

    15 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/15/2882291/0/en/Olema-Oncology-Announces-Promising-New-Data-for-Palazestrant-in-Combination-with-Ribociclib-Presented-at-the-2024-ESMO-Breast-Cancer-Congress.html

    GLOBENEWSWIRE
    15 May 2024
    Share Share
    Olema Oncology Q1 2024 Financials, Corporate Update
    Olema Oncology Q1 2024 Financials, Corporate Update

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2878169/0/en/Olema-Oncology-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share